ClinicalTrials.gg
CompletedNCT03155347Updated Nov 28, 2023

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

A Phase 3 interventional study of Tocilizumab and MTX in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 20 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
17th of 110
340 · median 97
Started
2017
the only one that year
Phase 3
65 of 110
none open now
Registered
96th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is the only one that started in 2017, is one of 65 in phase 3, and was the 96th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multi-center, parallel-group study to evaluate the efficacy and safety of subcutaneous (SC) tocilizumab (162 milligrams [mg] every 2 weeks [Q2W]) given as monotherapy and in combination with MTX versus MTX given as monotherapy, in participants with moderate to severe active rheumatoid arthritis (RA) who have inadequate response to current DMARD therapy. The study comprises a 24-week double-blind treatment phase, followed by a 24-week extension phase.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese participants who are located in mainland China with RA of greater than or equal to (>=) 6 months' duration from onset of the disease, diagnosed according to the revised 1987 ACR criteria and receiving treatment on an outpatient basis
  • Participants must have discontinued etanercept (or YiSaiPu) for >= 2 weeks, infliximab, certolizumab, golimumab, abatacept or adalimumab for >= 8 weeks, anakinra for >= 1 week prior to randomization
  • Have received oral MTX at a stable dose for at least 12 weeks prior to baseline (MTX dose 10 to 25 mg) and experience of failing at least one non-biologic DMARD including MTX
  • All treatment with non-biological DMARDs except MTX should be withdrawn at least 2 weeks prior to baseline (leflunomide for >= 12 weeks or >= 14 days after standard cholestyramine or activated charcoal washout, azathioprine for >= 4 weeks)
  • SJC >= 6 (on the basis of 66 joint counts) and TJC >= 8 (on the basis of 68 joint counts) at screening and baseline with at least 3 months of treatment with permitted DMARDs
  • Participants must have either high sensitive CRP >= 10 milligrams per liter (mg/L) or ESR >=28 millimeters per hour (mm/hr) at screening
  • Oral (\<=10 mg/day prednisone or equivalent) and nonsteroidal anti-inflammatory drug (NSAIDs; up to the maximum recommended dose per local standard of care) are permitted if the dose has been stable for at least 4 weeks prior to baseline
  • All treatment with Chinese traditional medicine and/or herb medicine for RA treatment should be withdrawn at least 2 weeks prior to baseline
  • Females of and males with female partners of childbearing potential may participate only if using a reliable means of as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  • Participants with major surgery or planned major surgery, rheumatic disease other than RA, and functional class IV (as defined by the ACR Classification of Functional Status in RA)
  • Participants with unsuccessful treatment with an anti-tumor necrosis factor (anti-TNF) agent; previous treatment with any cell-depleting therapies including agents and janus kinase (JAK) inhibitors or any other new agents which have DMARD/DMARD-like effect; treatment with intravenous (IV) gamma-globulin, plasmapheresis, or Prosorba column; treatment with alkylating agents
  • Intra-articular or parenteral and/or immunization with a live/attenuated vaccine within 4 weeks prior to baseline
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Primary or secondary immunodeficiency (history of or currently active)
  • Evidence of serious uncontrolled concomitant diseases and disease states; evidence of active malignant disease
  • Participants with abnormal haematological parameters, abnormal renal and hepatic parameters
  • Positive for either surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and/or virus (HCV) antibody
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    Tocilizumab + MTX

    Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR \<= 3.2).

    Drug: Tocilizumab · Drug: MTX

  • Experimental
    Tocilizumab + Placebo Matched to MTX

    Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR \<= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR \<= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.

    Drug: Tocilizumab · Drug: MTX · Drug: Placebo Matched to MTX

  • Active comparator
    Placebo Matched to Tocilizumab + MTX

    Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR \<= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR \<= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.

    Drug: Tocilizumab · Drug: MTX · Drug: Placebo Matched to Tocilizumab

Interventions

  • Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.

    Also known as: RO4877533

  • DrugMTX

    Participants will receive MTX stable doses at 10 to 25 mg orally.

  • DrugPlacebo Matched to MTX

    Placebo matched to MTX.

  • DrugPlacebo Matched to Tocilizumab

    Placebo matched to tocilizumab.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology (ACR) 20 (ACR20) Response at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Low Disease Activity at Week 24, Defined as Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Score of Less Than or Equal to (<=) 3.2

    Time frame: Week 24

  2. Percentage of Participants With Remission at Week 24, Defined as DAS28-ESR Score of Less Than (<) 2.6

    Time frame: Week 24

  3. Change From Baseline in Tender Joint Count (TJC) at Week 24

    Time frame: Baseline, Week 24

  4. Change From Baseline in Swollen Joint Count (SJC) at Week 24

    Time frame: Baseline, Week 24

  5. Change From Baseline in C-reactive Protein (CRP) Levels at Week 24

    Time frame: Baseline, Week 24

  6. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 24

    Time frame: Baseline, Week 24

  7. Change From Baseline in the Patient's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score at Week 24

    Time frame: Baseline, Week 24

  8. Change From Baseline in the Physician's Global Assessment of Disease Activity VAS Score at Week 24

    Time frame: Baseline, Week 24

  9. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

    Time frame: Baseline, Week 24

  10. Change From Baseline in the Patient's Pain VAS at Week 24

    Time frame: Baseline, Week 24

  11. Change From Baseline in DAS28-ESR at Week 24

    Time frame: Baseline, Week 24

  12. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 56 weeks

  13. Percentage of Participants With anti-Tocilizumab Antibody

    Time frame: Baseline, Week 12, Week 24, Week 48, at the time of withdrawal up to approximately 48 weeks

  14. Serum Interleukin-6 (IL-6) Levels

    Time frame: Baseline, predose (Hour 0) on Weeks 2, 4, 8, 12, 16, 24, 48

  15. Serum Soluble Interleukin-6 Receptor (sIL-6R) Levels

    Time frame: Baseline, predose (Hour 0) on Weeks 2, 4, 8, 12, 16, 24, 48

  16. Maximum Observed Plasma Concentration (Cmax) of Tocilizumab

    Time frame: predose (Hour 0) and 6-hours postdose on Day 0, Day 84; predose (Hour 0) on Day 14 and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  17. Minimum Observed Plasma Concentration (Cmin) of Tocilizumab

    Time frame: predose (Hour 0) on Day 0, 14, 84, and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  18. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tocilizumab

    Time frame: predose (Hour 0) and 6-hours postdose on Day 0, Day 84; predose (Hour 0) on Day 14 and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  19. Plasma Decay Half-Life (t1/2) of Tocilizumab

    Time frame: predose (Hour 0) and 6-hours postdose on Day 0, Day 84; predose (Hour 0) on Day 14 and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  20. Area Under the Curve from Time Zero to end of dosing interval (AUCtau) of Tocilizumab

    Time frame: predose (Hour 0) and 6-hours postdose on Day 0, Day 84; predose (Hour 0) on Day 14 and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  21. Accumulation Ratio for Area Under the Concentration Time Curve (Rac, AUC) of Tocilizumab

    Time frame: predose (Hour 0) and 6-hours postdose on Day 0, Day 84; predose (Hour 0) on Day 14 and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  22. Accumulation Ratio for Maximum Observed Plasma Concentration (Rac, Cmax) of Tocilizumab

    Time frame: predose (Hour 0) and 6-hours postdose on Day 0, Day 84; predose (Hour 0) on Day 14 and 98; on Day 1, 2, 3, 5, 7, 10, 85, 86, 87, 89, 91, and 94

  23. Accumulation Ratio for Minimum Observed Plasma Trough Concentration (Rac, Cmin) of Tocilizumab

    Time frame: predose (Hour 0) on Day 14, 84

  24. Plasma Trough Concentration (Ctrough) of Tocilizumab

    Time frame: predose (Hour 0) on Day 0, 14, 28, 56, 84, 98, 112, 140, 168, and 336

  25. Percentage of Participants With ACR50 Responses at Week 24

    Time frame: Week 24

  26. Percentage of Participants With ACR70 Responses at Week 24

    Time frame: Week 24

07

Study locations

20 sites
  • The First Affiliated Hospital of Baotou Medical College
    Baotou, 014010, China
  • China-Japan Friendship Hospital
    Beijing City, 100029, China
  • Peking University First Hospital
    Beijing City, 100034, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Union Hospital
    Beijing, 100730, China
  • Affiliated Hospital of Bengbu Medical College
    Bengbu, 233004, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • The 1st Affiliated Hospital of Harbin Medical University
    Harbin, 150001, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, 230022, China
  • Affiliated Hospital of Inner Mongolia Medical College
    Hohhot, 010050, China
  • The First Hospital of Jiaxing
    Jiaxing, 314001, China
  • Qilu Hospital of Shandong University
    Jinan, 250012, China
  • The First Affilliated Hospital of Kunming Medical College
    Kunming, 650032, China
  • Jiangsu Province Hospital
    Nanjing, 210008, China
  • Pingxiang People Hospital
    Pingxiang City, 337000, China
  • Shengjing Hospital of China Medical University
    ShenYang, 110004, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, China
  • Tianjin Medical University General Hospital
    Tianjin, 300052, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2022, 60 months.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 60 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2017
First posted
May 16, 2017
StartActual
Aug 2, 2017
Primary completionActual
Aug 8, 2022
CompletionActual
Aug 8, 2022
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03155347
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 16, 2017
Start date
Aug 2, 2017
Primary completion
Aug 8, 2022
Completion
Aug 8, 2022
Last update
Nov 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Methotrexate

Start the discussion